Lenz Therapeutics Inc. announced the US Food and Drug Administration (FDA) approval of Vizz (aceclidine ophthalmic solution) 1.44%, an aceclidine-based eye drop for the treatment of presbyopia in adults. Vizz contracts the iris sphincter muscle resulting in a pinhole effect and achieves a sub-2 mm pupil that extends depth of focus to significantly improve near vision without causing a myopic shift, according to the company. Samples are anticipated in the United States as early as October 2025, with commercial product to be broadly available by mid-Q4 2025.

In other news, Lenz announced that Corxel Pharmaceuticals has submitted the new drug application (NDA) for LNZ100 for patients who have presbyopia to the Center for Drug Evaluation of the National Medical Products Administration (NMPA) of the People’s Republic of China. Lenz licensed the Greater China rights to Corxel for the development and commercialization of LNZ100 in April 2022.